Malaysia Pharmas Maneuver For Global Role In Generics, Clinical Research
This article was originally published in PharmAsia News
Malaysia’s pharmaceutical industry has been maneuvering quietly in the past few years to play a larger role in what is expected to be a $1.1 trillion global drug market by 2015.
You may also be interested in...
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.